Effectiveness of favipiravir in comparison with Tenofovir Alafenamid in patients with COVID-19

Evaluation of safety and effectiveness of favipiravir in comparison with Tenofovir Alafenamid in hospitalized patients with COVID-19

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150808023559N23

Enrollment

100

Registered

2020-10-11

Start date

2020-09-20

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: Group receiving Favipiravir. This group will receive stat dose of eight 200 mg Favipiravir tablets(Nafas farmed Co, Iran) followed by Favipiravir 600 mg three times

Eligibility

Sex/Gender

All

Age

16 Years to 100 Years

Inclusion criteria

Inclusion criteria: Diagnosis of COVID-19 based on chest CT scan or positive PCR test for COVID-19 Requiring hospitalization Patient's age between 16 and 100 years Signing informed consent form

Exclusion criteria

Exclusion criteria: Receiving other antiviral medicationsrenal failure Pregnancy HIV Lactation Renal failure

Design outcomes

Primary

Measure	Time frame
Hospital mortality. Timepoint: Up to two weeks after the intervention on a daily basis. Method of measurement: Patient medical records.	—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: From the time of hospitalization to the patient's discharge from the hospital. Method of measurement: Patient medical records.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomaieh Matin

Ardabil University of Medical Sciences

s.matin@arums.ac.ir+98 45 3325 1410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026